FT516 in Subjects With Advanced Hematologic Malignancies

Stopped early · Phase 1

Conditions studied: Acute Myelogenous Leukemia, B-cell Lymphoma

In brief

This is a Phase 1/1b dose-finding study of FT516 as monotherapy in acute myeloid leukemia (AML) and in combination with CD20 directed monoclonal antibodies in B-cell lymphoma. The study includes three stages: dose escalation, safety confirmation, and dose expansion.

Key facts

Study ID

NCT04023071

Run by

Fate Therapeutics

People needed

72

Starts

2019-10-04

Expected to finish

2023-10-23

Last updated by the study team

2023-10-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Mayo Clinic — Phoenix, Arizona, United States
• UC San Diego — San Diego, California, United States
• University of Colorado, Denver — Denver, Colorado, United States
• University of Minnesota Masonic Cancer Center — Minneapolis, Minnesota, United States
• UT Southwestern — Dallas, Texas, United States
• MD Anderson Cancer Center — Houston, Texas, United States
• Swedish Cancer Institute — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.